Title : Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.

Pub. Date : 2013 May

PMID : 23584298






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Although vandetanib improved median PFS in EGFR mutation patients with epidermal growth factor receptor tyrosine kinase inhibitor-resistance compared with EGFR wild-type, there was no OS advantage. vandetanib epidermal growth factor receptor Homo sapiens
2 Although vandetanib improved median PFS in EGFR mutation patients with epidermal growth factor receptor tyrosine kinase inhibitor-resistance compared with EGFR wild-type, there was no OS advantage. vandetanib epidermal growth factor receptor Homo sapiens
3 Although vandetanib is no longer in development in NSCLC, identification of a molecular phenotype that responds to dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition would contribute to the field. vandetanib epidermal growth factor receptor Homo sapiens